APA (7th ed.) Citation

Dimopoulos, M. A., Leleu, X., Moreau, P., Attal, M., Richardson, P. G., Liberati, A. M., . . . Yong, K. (2019). Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis. Clinical lymphoma, myeloma & leukemia, 19, e254. https://doi.org/10.1016/j.clml.2019.09.420

Chicago Style (17th ed.) Citation

Dimopoulos, Meletios A., et al. "Effect of Isatuximab Plus Pomalidomide/dexamethasone on Renal Impairment in Relapsed/refractory Multiple Myeloma: ICARIA-MM Study Subgroup Analysis." Clinical Lymphoma, Myeloma & Leukemia 19 (2019): e254. https://doi.org/10.1016/j.clml.2019.09.420.

MLA (9th ed.) Citation

Dimopoulos, Meletios A., et al. "Effect of Isatuximab Plus Pomalidomide/dexamethasone on Renal Impairment in Relapsed/refractory Multiple Myeloma: ICARIA-MM Study Subgroup Analysis." Clinical Lymphoma, Myeloma & Leukemia, vol. 19, 2019, p. e254, https://doi.org/10.1016/j.clml.2019.09.420.